Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients
A Randomized, Controlled Crossover Trial Evaluating Oral Testosterone in the Treatment of Fatigue in Male Multiple Sclerosis Patients
Sponsor: Consortium of Multiple Sclerosis Centers
Terminated
Poor recruitment
Other terminated trials from Consortium of Multiple Sclerosis Centers
More terminations from Consortium of Multiple Sclerosis Centers
This PHASE2 trial investigates Fatigue and Multiple Sclerosis and is currently terminated or withdrawn. Consortium of Multiple Sclerosis Centers leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Feb 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Consortium of Multiple Sclerosis Centers
- Health Sciences Centre, Winnipeg, Manitoba
- Manitoba Medical Service Foundation
- University of Manitoba
For direct contact, visit the study record on ClinicalTrials.gov .